Adaptimmune Therapeutics Plc (ADAPY)
0.037
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Adaptimmune Therapeutics Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 32.43M |
| October 01, 2026 | 32.69M |
| September 30, 2026 | 32.69M |
| September 29, 2026 | 29.51M |
| September 28, 2026 | 29.72M |
| September 25, 2026 | 29.38M |
| September 24, 2026 | 28.72M |
| September 23, 2026 | 29.51M |
| September 22, 2026 | 29.59M |
| September 21, 2026 | 29.67M |
| September 18, 2026 | 28.58M |
| September 17, 2026 | 28.72M |
| September 16, 2026 | 29.25M |
| September 15, 2026 | 29.25M |
| September 14, 2026 | 28.98M |
| September 11, 2026 | 28.62M |
| September 10, 2026 | 28.75M |
| September 09, 2026 | 29.25M |
| September 08, 2026 | 29.51M |
| September 04, 2026 | 29.72M |
| September 03, 2026 | 29.51M |
| September 02, 2026 | 29.25M |
| September 01, 2026 | 29.78M |
| August 31, 2026 | 28.58M |
| August 28, 2026 | 30.04M |
| Date | Value |
|---|---|
| August 27, 2026 | 30.28M |
| August 26, 2026 | 29.63M |
| August 25, 2026 | 29.25M |
| August 24, 2026 | 29.40M |
| August 21, 2026 | 29.78M |
| August 20, 2026 | 29.78M |
| August 19, 2026 | 29.78M |
| August 18, 2026 | 29.43M |
| August 17, 2026 | 30.31M |
| August 14, 2026 | 30.31M |
| August 13, 2026 | 29.78M |
| August 12, 2026 | 30.31M |
| August 11, 2026 | 30.57M |
| August 10, 2026 | 30.04M |
| August 07, 2026 | 30.57M |
| August 06, 2026 | 30.84M |
| August 05, 2026 | 29.91M |
| August 04, 2026 | 31.10M |
| August 03, 2026 | 30.31M |
| July 31, 2026 | 31.05M |
| July 30, 2026 | 31.63M |
| July 29, 2026 | 31.10M |
| July 28, 2026 | 31.37M |
| July 27, 2026 | 30.57M |
| July 24, 2026 | 30.36M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oxford Biomedica Plc | -- |
| Kiniksa Pharmaceuticals International Plc | 5.393B |
| Autolus Therapeutics Plc | 638.46M |
| Bicycle Therapeutics Plc | -324.57M |
| Scancell Holdings Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -30.72M |
| Revenue (Quarterly) | 13.85M |
| Total Expenses (Quarterly) | 44.56M |
| EPS Diluted (Quarterly) | -0.1163 |